IQVIA Posts Q2 Beat, Hikes Revenue Outlook to $17.28B - $17.48B

IQV beat on both lines in the second quarter and raised full-year guidance, sending the stock up more than 5%. Revenue of $4.368 billion rose 8.7% year over year and topped the roughly $4.30 billion consensus, while adjusted diluted EPS of $3.15 climbed 12.1% and cleared the $3.03 estimate. Adjusted EBITDA reached $994 million, up 9.2%.

Management lifted the full-year revenue range to $17.28 billion to $17.48 billion, a midpoint of roughly $17.38 billion against a prior midpoint near $17.25 billion, and raised the adjusted EPS outlook to about $12.90 at the midpoint. The upward revision is modest in absolute terms but notable in direction: contract research has spent two years absorbing biotech funding weakness and cautious pharma R&D budgets, and a guidance raise is the clearest signal yet that bookings have stabilized.

The operating leverage is what to watch from here. EPS grew faster than revenue and EBITDA grew faster than sales, which suggests IQVIA is converting a recovering demand environment into margin rather than simply chasing volume. The risk sits on the other side of the same trade: if the raise was driven by a small number of large awards rather than broad-based bookings, the second half will not sustain the same rate of improvement.

Related Stocks

• IQV
• FDS